Urinary Stone Agents

Urinary stone agents represent a formulary and compendial classification rather than a single pharmacologic mechanism, encompassing miscellaneous genitourinary medications utilized to prevent or manage nephrolithiasis and urolithiasis

Urinary stone agents represent a formulary and compendial classification rather than a single pharmacologic mechanism, encompassing miscellaneous genitourinary medications utilized to prevent or manage nephrolithiasis and urolithiasis

Rather than sharing a solitary pathway, medications in this category target specific biochemical drivers of stone crystallization; examples include thiol-disulfide exchange agents like tiopronin, which enhance cystine solubility to prevent cystine stone formation in cystinuria, and urease inhibitors such as acetohydroxamic acid, which lower urinary ammonia and alkalinity to mitigate infection-induced struvite stones Clinically, these agents are primarily indicated as targeted adjunctive therapie...

Rather than sharing a solitary pathway, medications in this category target specific biochemical drivers of stone crystallization; examples include thiol-disulfide exchange agents like tiopronin, which enhance cystine solubility to prevent cystine stone formation in cystinuria, and urease inhibitors such as acetohydroxamic acid, which lower urinary ammonia and alkalinity to mitigate infection-induced struvite stones Clinically, these agents are primarily indicated as targeted adjunctive therapie...